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Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease without clearly
known disease causes. Recent epidemiological and animal studies suggest that the
supplementation of dietary antioxidants (e.g., vitamins C and E) decreases cancer risk,
implying that increased reactive oxygen species (ROS) may play a role in pancreatic
carcinogenesis. However, oncogenic Kras mutations (e.g., KrasG12D), which are present
in more than 90% of PDAC, have been proven to foster low intracellular ROS levels. Here,
oncogenic Kras activates expression of a series of anti-oxidant genes via Nrf2 (nuclear
factor, erythroid derived 2, like 2) and also mediates an unusual metabolic pathway of
glutamine to generate NADPH. This can then be used as the reducing power for ROS
detoxification, leading collectively to low ROS levels in pancreatic pre-neoplastic cells
and in cancer cells. In adult stem cells and cancer stem cells, low ROS levels have
been associated with the formation of a proliferation-permissive intracellular environment
and with perseverance of self-renewal capacities. Therefore, it is conceivable that low
intracellular ROS levels may contribute significantly to oncogenic Kras-mediated PDAC
formation.
Keywords: pancreatic cancer, redox equilibrium, reactive oxygen species, oncogenic Kras, pancreatic cancer stem
cells, KrasG12D
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggres-
sive tumor entity without clearly known disease causes (Kong
et al., 2011; Siegel et al., 2013). Oncogenic KRAS (v-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog) mutations (e.g.,
KRASG12D or KRASG12V) have been considered as the initiat-
ing genetic event for this disease (Kong et al., 2011). Recently,
prospective studies have demonstrated that dietary antioxidants
(e.g., vitamins C and E) significantly decreased cancer risk, under-
scoring an important role of the redox equilibrium in the etiology
of PDAC (Gong et al., 2010; Banim et al., 2012; Heinen et al.,
2012). Furthermore, genetic variations in antioxidant genes seem
to modify the risk to develop PDAC in humans (Tang et al.,
2010). In line, long-term treatment with δ-tocotrienol (a bioactive
vitamin E derivative) which has putative anti-oxidative activity
dramatically inhibited KrasG12D-driven formation of pancreatic
intraepithelial neoplasms (mPanINs) in a genetically engineered
mouse model (GEMM) of pancreatic cancer (Husain et al., 2011,
2013; Shin-Kang et al., 2011). These data suggest that a systemic
reduction in the production of reactive oxygen species (ROS) may
prevent/delay the development of PDAC. Paradoxically, recent
studies have also demonstrated that oncogenic KrasG12D mediates
activation of metabolic programs, which effectively detoxify ROS
and thus reduce ROS levels in pancreatic pre-neoplastic cells and
in cancer cells. Furthermore, low intracellular ROS levels seem to
be essential for KrasG12D-driven carcinogenesis in mice (deNicola
et al., 2011; Son et al., 2013). In this case, a “chemo-” preven-
tive effect of dietary antioxidants cannot be explained by reduced
intracellular ROS levels in pancreatic epithelial cells. Thus, we
reviewed and discussed the potential biological significance of
KrasG12D-mediated ROS-detoxifying networks.
ONCOGENIC Kras INITIATES PANCREATIC CANCER
Characterization of human cancer genomes confirmed that more
than 90% of human PDACs harbor oncogenic KRAS mutations
(Almoguera et al., 1988; Smit et al., 1988). The mutated KRAS
encodes a protein locked in a constitutively active state, lead-
ing to persistent downstream signals such as activation of the
RAF-MEK-ERK (extracellular signal-regulated kinase) cascade
(Barbacid, 1987). The ability of oncogenic KRAS in initiating
PDAC has been demonstrated in GEMMs of pancreatic cancer.
Here, pancreas-specific expression of KrasG12D recapitulated the
whole spectrum of human PDAC pathologies, from its precur-
sor lesions to locally invasive and metastatic entities (Hingorani
et al., 2003). Recent studies have demonstrated that the activity
of KrasG12D is required for all stages of carcinogenesis includ-
ing inception, progression and metastasis because inactivation
of KrasG12D using genetic approaches invariably reversed the
ongoing carcinogenic process (Collins et al., 2012). However, it
remains largely elusive how KrasG12D exactly promotes PDAC
development.
REACTIVE OXYGEN SPECIES (ROS) METABOLISM
Chemically reactive molecules containing oxygen, which are
usually termed as ROS, consist of free radical ROS [e.g., oxy-
gen ions (O−2 )] and non-radical ROS [e.g., peroxide (H2O2)].
The free radical ROS has unpaired electrons in the molecular
orbital whereas non-radical ROS contains no unpaired electrons
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(Shi et al., 2012). ROS formation, as a natural byproduct of aer-
obic metabolism, can be derived from exogenous and endoge-
nous sources (Castro and Freeman, 2001). As for the exogenous
sources, substances (e.g., metals and chemicals) inducing ROS
formation can be directly metabolized to radicals in cells or
can trigger intracellular ROS production (Bonney et al., 1991;
Halliwell and Aruoma, 1991; Dreher and Junod, 1996; Jaruga
and Dizdaroglu, 1996; Wang et al., 1998). Under physiological
circumstances, the mitochondrion is an intracellular organelle
which is responsible for energy production through cellular res-
piration. However, the leaking electron from the mitochondrial
electron transport chain eventually interacts with oxygen and
generates superoxide radicals, producing approximately 98% of
the endogenous ROS (Freeman and Crapo, 1982; McCord, 2000;
Salvador et al., 2001). Apart from the mitochondrion, biochem-
ical reactions within the endoplasmatic reticulum (ER), the per-
oxisome or the cytoplasm also generate additional ROS (Butler
and Hoey, 1993; Conner and Grisham, 1996; Li and Jackson,
2002; Klaunig and Kamendulis, 2004; Valko et al., 2004). For
instance, cytochrome P450 in the ER uses oxygen to oxidize and
to detoxify foreign compounds; a process in which ROS are gen-
erated (Butler and Hoey, 1993). In addition, membrane-bound
NADPH (nicotinamide adenine dinucleotide phosphate) oxidase
in immune cells (e.g., neutrophils and macrophages) produces
ROS via a biochemical process known as the respiratory burst,
which is essential for these cells to eliminate bacteria (Conner and
Grisham, 1996).
Since excessive ROS can cause oxidative damage to macro-
molecules (e.g., DNA and lipids) and can alter intracellular
signal transduction (e.g., through NF-κB), intracellular ROS
is constantly eliminated via a sophisticated ROS-detoxifying
system including non-enzymatic antioxidants (e.g., Vitamins
C and E) and enzymatic antioxidants [such as superoxide
dismutase (SOD), catalase (CAT) and glutathione peroxides
(GPX)] (Mates et al., 1999; McCall and Frei, 1999). Notably,
the majority of these enzymes require the activity of reduced
glutathione (GSH) which further relies on NADPH. In this
case, NADPH provides the ultimate reducing power for ROS
detoxification. Taken together, both non-enzymatic antioxi-
dants and enzymatic antioxidants act as an “antioxidant net-
work” which maintains a fine-tuned intracellular redox balance
(Sies et al., 2005).
KrasG12D MAINTAINS LOW ROS LEVELS IN PDAC CELLS
Until today, it remains elusive how KrasG12D promotes PDAC.
Recent studies demonstrated that KrasG12D induces maintenance
of low intracellular ROS levels via the transcription factor Nrf2
(nuclear factor, erythroid derived 2, like 2), which is a master
switch in the antioxidant network (deNicola et al., 2011). To
provide a reducing power for this Nrf2-mediated antioxidant pro-
gram, KrasG12D promotes a concerted metabolic program (e.g.,
thorough glutamine and fatty acid) that continually sustains the
intracellular NADPH/NADP+ ratio (Khasawneh et al., 2009; Son
et al., 2013) (Figure 1).
An earlier study demonstrated that ectopic expression of onco-
genic Ras increased ROS production through NADPH-oxidase
(Nox; Irani et al., 1997). Later on, a follow-up study provided
FIGURE 1 | Schema showing how oncogenic Kras induces low
intracellular ROS levels.
evidence that such an increased ROS generation is functionally
relevant to oncogenic Ras-mediated malignant transformation of
NIH3T3 cells (Mitsushita et al., 2004). However, this concept
has been challenged by a recent study which substantiated that
ROS production was actually repressed by endogenous expres-
sion of the KrasG12D allele in mouse cell lines (deNicola et al.,
2011). Further investigation uncovered that KrasG12D activated
Nrf2 via MAPK pathways (mitogen-activated protein kinase),
which then initiated a set of antioxidant programs. Consistently,
human PanINs and PDACs exhibit activation of NRF2 and
have low ROS levels in comparison to normal pancreatic ducts
cells. NRF2, which is negatively regulated by KEAP1 (kelch-like
ECH-associated protein 1), controls the expression of a series
of proteins involved in different steps of ROS detoxification—
such as NADPH generation (Cullinan et al., 2004; McMahon
et al., 2006; Hayes and McMahon, 2009). Unlike many other
tumor entities such as lung cancers (Shibata et al., 2008; Kim
et al., 2010), however, PDACs rarely harbor somatic mutations
in either the KEAP1 or NRF2 genes that usually result in an
active NRF2. Hence, the Nrf2-mediated antioxidant program in
PDAC is activated in an oncogenic Kras-dependent manner. In
line, silencing of Kras or blockade of the MAPK pathway effec-
tively decreased Nrf2 expression and increased intracellular ROS
levels.
As early illustrated, ROS detoxification is a biochemical pro-
cess that consumes NADPH (NADPH provides the reducing
power). Thus, generation and maintenance of constant intra-
cellular NADPH levels is essentially important. In this regard,
a previous study demonstrated that KrasG12D enhanced glycol-
ysis of PDAC cells and that it directed glycolytic intermediates
into the non-oxidative pentose phosphate pathway (PPP) whereas
the NAPDH-producing oxidative arm of the PPP remained unaf-
fected (Ying et al., 2012). These data suggest that PDAC cells
might use other NADPH-producingmetabolic pathways tomain-
tain intracellular NADPH levels. Indeed, a recent study uncov-
ered a distinct metabolic pathway of glutamine which is used
by PDAC cells to generate NADPH (Son et al., 2013). Briefly,
glutamine-derived aspartate (Asp) and α-ketoglutarate (α-KG)
are converted into oxaloacetate (OAA) via aspartate transami-
nase (GOT1). The OAA is metabolized into malate by malate
dehydrogenase (MDH1) and subsequently into pyruvate by malic
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enzyme (ME1). Conversion from malate to pyruvate then creates
NADPH, which is important for maintaining the redox balance of
PDACs because inactivation of any component of this metabolic
pathway increased intracellular ROS levels and affected tumor
growth (Cairns et al., 2011). Though the tumor environment
of PDAC is usually depleted of glutamine, a recent study sub-
stantiated that PDAC cells containing oncogenic Kras showed an
increased protein uptake by macropinocytosis. These internal-
ized proteins are then metabolized into glutamine that is fueled
into the NDAPH-producing process (Commisso et al., 2013). It
has also been demonstrated that the KrasG12D-expressing pan-
creas exhibited increased fatty acid oxidation (Khasawneh et al.,
2009). Since fatty acid oxidation is a NADPH-generating process
(Jeon et al., 2012), it remains to be defined whether increased fatty
acid oxidation also contributes to the maintenance of NADPH
levels.
In conclusion, collaboration between Nrf2-mediated ROS
detoxification and the NADPH-generating metabolic program
collectively contributes to a “reduced” intracellular environment
(e.g., low ROS levels). Since both of these depend on the activ-
ity of oncogenic Kras, it is conceivable that such an intracel-
lular environment constitutes an important step in pancreatic
carcinogenesis.
THE TUMOR-SUPPRESSING FUNCTION OF ANTIOXIDANTS
DOES NOT CONTRADICT TUMOR-PROMOTING EFFECTS OF
ONCOGENIC Kras-MEDIATED LOW INTRACELLULAR ROS
LEVELS
As earlier illustrated, prospective studies have suggested an
association between dietary antioxidants and a decreased risk
for developing pancreatic cancer (Gong et al., 2010; Banim
et al., 2012; Heinen et al., 2012). Besides, certain antioxi-
dants (especially δ-tocotrienol) have chemo-preventive effects in
GEMMs of pancreatic cancer (Husain et al., 2011, 2013; Shin-
Kang et al., 2011). Interestingly, these data rather point to a
tumor-suppressing function of antioxidants in pancreatic cancer.
However, the emergence of this evidence does not necessar-
ily argue against the tumor-promoting functions of oncogenic
Kras-mediated low intracellular ROS levels. Firstly, the tumor-
suppressing function of antioxidants may be attributed to their
effects on the immune system and especially T cell immunity.
Recently, it has been shown that antitumor T cell immunity
plays a crucial role in the early stages of pancreatic carcino-
genesis (Bayne et al., 2012; Pylayeva-Gupta et al., 2012). In
this regard, the dietary supplementation of antioxidants (e.g.,
vitamins E or C) has been proven to significantly enhance T
cell immunity in humans (Burgess and Johansen, 1976; Meydani
et al., 1997; Malmberg et al., 2002). Therefore, antioxidants
may execute their tumor-suppressing functions by promoting
antitumor immunity. Secondly, it remains largely unknown
whether ROS levels in the pancreas (especially in epithelial cells)
are actually affected by the intake of dietary antioxidant in
humans. Thus, it is difficult to evaluate the contribution of their
antioxidative effects to the development of pancreatic cancer.
Lastly, some antioxidants display antitumor activities indepen-
dent of their antioxidative effects. For instance, δ-tocotrienol,
which has been used for chemo-prevention of pancreatic can-
cer in animal studies, contains an unsaturated isoprenoid side
chain that has a unique antitumor property (Shin-Kang et al.,
2011). Taken together, further studies are required to clarify
how/why antioxidants execute their tumor-suppressor functions
on oncogenic Kras-mediated low intracellular ROS levels in the
pancreas.
LOW ROS LEVELS IN DIFFERENT BIOLOGICAL SYSTEMS
Although the biological significance of such an oncogenic Kras-
mediated reductive intracellular environment remains unclear,
this phenomenon has been widely described in other biolog-
ical systems (Table 1). For example, when yeast cells are cul-
tured under nutrient-limited conditions, they display a periodic
metabolic cycle alternating between glycolysis and respiration.
Their cell cycle is tightly restricted to the reductive phase of
the metabolic cycle, which guarantees that DNA replication only
occurs during glycolysis when the oxidative damage from res-
piration on the genome is minimal. Such a circadian rhythm
that coordinates the metabolic and cell division cycles in situa-
tions where resources are limited, simply reflects an evolutionarily
conserved means of preserving genome integrity (Chen et al.,
2007). Silencing of a DNA checkpoint kinase abolishing such
a rhythm allows DNA synthesis outside of the reductive phase
but at the cost of increased spontaneous mutation rates. In
adult stem cells, a similar nutrient-limited microenvironment
(hypoxia) with low intracellular ROS levels also exists (Suda et al.,
2011; Zhang and Sadek, 2013). Here, low ROS levels have been
shown to be essential for maintaining the stem cell functions of
hematopoietic stem cells (HSCs) in that the ROSlow cell pop-
ulation expressed high levels of stemness-associated molecules
such as Notch1 and telomerase; it also had a higher self-renewal
potential than the ROShigh population of cells (Jang and Sharkis,
2007). Similarly, mammary epithelial stem cells have low ROS
Table 1 | Cellular systems with low intracellular ROS levels.
References Species/organ system Condition Biological significance
Chen et al., 2007 Yeast Nutrient-limited Preserve integrity of the genome
Jang and Sharkis, 2007 Mouse/hematopoietic stem cells Hypoxic Reserve stem cell function
Diehn et al., 2009 Mouse/mammary epithelial stem cells – Maintain stemness
Diehn et al., 2009 Human/breast CSCs Cancer microenvironment Preserve tumor-initiating capacity
and radio-resistance
Dong et al., 2013 Cell lines/basal-like breast cancer CSCs Inhibit ROS production by metabolic
reprogramming
Promote CSC-like properties
www.frontiersin.org September 2013 | Volume 4 | Article 246 | 3
Kong et al. ROS in pancreatic cancer
levels (Diehn et al., 2009). Low ROS levels have been described
in another type of “stem” cells—the “cancer stem” cells (CSCs)
or “tumor-initiating” cells (TICs) (Shi et al., 2012). Historically,
CSCs have been defined as a subset of cancer cells that are
responsible for initiation, maintenance and metastasis of can-
cer (Lapidot et al., 1994). A seminal study demonstrated that
human breast CSCs contained lower ROS levels than their
non-tumorigenic progeny (Diehn et al., 2009). These low ROS
levels rendered the CSCs highly resistant toward irradiation-
induced DNA damage and cell death. Consistently, a recent
study provided functional evidence that CSC-like properties in
basal-like breast cancer are induced, when ROS production is
inhibited by metabolic reprogramming of glucose metabolism
[e.g., when more NADPH is generated, (Dong et al., 2013)].
Taken together, low ROS levels in other biological systems
appear to be associated with stemness properties of cells
in mammals or with a proliferation-permissive intracellular
environment in low eukaryotic systems, both of which may
contribute to oncogenic Kras-mediated carcinogenesis in the
pancreas.
LOW ROS LEVELS AND PANCREATIC CARCINOGENESIS
Because early expansion of pancreatic stem/progenitor cells
accelerates KrasG12D-driven carcinogenesis in mice (Kong et al.,
2011), KrasG12D-induced low intracellular ROS levels may facil-
itate expansion of pancreatic stem/progenitor cells by creating a
proliferation-permissive intracellular environment. Furthermore,
despite a questionable general compliance of PDAC to the CSCs
concept, the heterogeneity of pancreatic cancer tissues indicates
that a subset of pancreatic cancer cells may have low intracellular
ROS levels in comparison to others.
CONCLUSION
The exact contribution of pre-neoplastic and cancer cells with
low ROS levels to PDAC initiation, progression and metastasis in
humans remains to be defined. Certainly, such a subset of cancer
cells may constitute a promising drug target for future thera-
pies. Though the Nrf2-mediated network has been proposed as a
potential drug target (Arlt et al., 2012), further studies on the con-
tribution of (low) ROS levels to the aggressiveness of pancreatic
cancer are warranted.
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